|| Checking for direct PDF access through Ovid
The end stage renal disease (ESRD) population is enriched with patients with HCV infection. However, lack of information about HCV serostatus in large ESRD and transplant registries in the United States (US) has limited research about outcomes among dialysis patients who have been infected with HCV and HCV-seropositive patients’ access to renal transplantation.We linked detailed clinical data, that included HCV sersostatus, from a large dialysis provider with US transplant registry data and examined outcomes among patients receiving chronic dialysis between 1/1/2004 – 12/31/2014. Using Cox and cause-specific hazards regression, we evaluated adjusted hazard (aHR) and subhazard ratios (SHR) of all-cause mortality, transplant wait-listing, and kidney transplantation associated with HCV seropositivity status.Among 442,171 chronic dialysis patients, 31,624 (7.2%) were seropositive for HCV. HCV infection was associated with a small elevation in the risk of death (aHR 1.09, 95% CI 1.07-1.11) but a substantial reduction in access to the kidney transplant waitlist (SHR 0.67, 95% CI 0.61 - 0.73). Once waitlisted, HCV+ patients underwent transplantation as rapidly as seronegative patients (SHR 1.11, 95% CI 0.97-1.29) and derived a substantial survival benefit from kidney transplantation (aHR 0.37, 95% CI 0.31-0.46) compared to dialysis (Figure 1). Additionally, the strategy of accepting an HCV+ donor kidney provided a survival advantage (aHR 0.67, 95% CI 0.51-0.87) compared to remaining on the waitlist to wait for a HCV-negative donor kidney.Dialysis patients with HCV have reduced access to kidney transplantation, despite deriving a significant survival benefit from transplantation. Future research must focus on identifying and removing barriers to waitlisting for these patients.NIH R21 DK108045.